AACR 2026 Poster | Targeted radionuclide therapy (TRT) with alpha and beta emitters provides a precise cancer treatment approach that improves outcomes while limiting systemic toxicity.

The development of new radiopharmaceuticals relies on robust in vitro and in vivo assays to assess target specificity, pharmacokinetics, biodistribution, resistance mechanisms, and therapeutic index.

Our results show that combining radiochemistry expertise with clinically relevant patient-derived models improves characterisation of novel radiopharmaceuticals and strengthens the predictive power of preclinical studies, ensuring new therapies align with clinical needs.

Meet the team at AACR 2026 at Booth 1418, Hall C (Ground Level).